Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus low-dose cytarabine versus placebo plus low-dose cytarabine in untreated AML patients ineligible for intensive chemotherapy
2016-003900-30Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Venetoclax + low-dose cytarabine with Placebo + low-dose cytarabine (2 arms). Primary endpoint: Overall Survival. Started Apr 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-003900-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003900-30.